Drugs intervention study in COVID-19 management
Abstract By 9 February 2021, the Coronavirus has killed 2,336,650 people worldwide and it has been predicted that this number continues to increase in year 2021. The study aimed to identify therapeutic approaches and drugs that can potentially be used as interventions in Coronavirus 2019 (COVID-19) management. A systematic scoping review was conducted. Articles reporting clinical evidence of therapeutic management of COVID-19 were selected from three different research databases (Google Scholar, PubMed, and Science Direct). From the database search, 31 articles were selected based on the study inclusion and exclusion criteria. This review paper showed that remdesivir and ivermectin significantly reduced viral ribonucleic acid (RNA) activity. On the other hand, convalescent plasma (CP) significantly improved COVID-19 clinical symptoms. Additionally, the use of corticosteroid increased survival rates in COVID-19 patients with acute respiratory distress syndrome (ARDS). Findings also indicated that both hydroxychloroquine and favipiravir were effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, lopinavir–ritonavir combination was not effective against COVID-19. Finally, ribavirin, galidesivir, and sofosbuvir showed potential therapeutic benefit in treating COVID-19, but there is a lack of clinical evidence on their effectiveness against SARS-CoV-2. Remdesivir, ivermectin, favipiravir, hydroxychloroquine, dexamethasone, methylprednisolone, and CP are the therapeutic agents that can potentially be used in COVID-19 management..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
Drug metabolism and drug interactions - 36(2021), 2 vom: 05. Apr., Seite 87-98 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Taher, Muhammad [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© 2021 Walter de Gruyter GmbH, Berlin/Boston |
|---|
| doi: |
10.1515/dmpt-2020-0173 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
GRUY00816472X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | GRUY00816472X | ||
| 003 | DE-627 | ||
| 005 | 20230811151427.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230811s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1515/dmpt-2020-0173 |2 doi | |
| 035 | |a (DE-627)GRUY00816472X | ||
| 035 | |a (DE-B1597)dmpt-2020-0173-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 084 | |a 44.38 |2 bkl | ||
| 100 | 1 | |a Taher, Muhammad |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Drugs intervention study in COVID-19 management |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2021 Walter de Gruyter GmbH, Berlin/Boston | ||
| 520 | |a Abstract By 9 February 2021, the Coronavirus has killed 2,336,650 people worldwide and it has been predicted that this number continues to increase in year 2021. The study aimed to identify therapeutic approaches and drugs that can potentially be used as interventions in Coronavirus 2019 (COVID-19) management. A systematic scoping review was conducted. Articles reporting clinical evidence of therapeutic management of COVID-19 were selected from three different research databases (Google Scholar, PubMed, and Science Direct). From the database search, 31 articles were selected based on the study inclusion and exclusion criteria. This review paper showed that remdesivir and ivermectin significantly reduced viral ribonucleic acid (RNA) activity. On the other hand, convalescent plasma (CP) significantly improved COVID-19 clinical symptoms. Additionally, the use of corticosteroid increased survival rates in COVID-19 patients with acute respiratory distress syndrome (ARDS). Findings also indicated that both hydroxychloroquine and favipiravir were effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, lopinavir–ritonavir combination was not effective against COVID-19. Finally, ribavirin, galidesivir, and sofosbuvir showed potential therapeutic benefit in treating COVID-19, but there is a lack of clinical evidence on their effectiveness against SARS-CoV-2. Remdesivir, ivermectin, favipiravir, hydroxychloroquine, dexamethasone, methylprednisolone, and CP are the therapeutic agents that can potentially be used in COVID-19 management. | ||
| 700 | 1 | |a Tik, Noratika |4 aut | |
| 700 | 1 | |a Susanti, Deny |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug metabolism and drug interactions |d De Gruyter, 1980 |g 36(2021), 2 vom: 05. Apr., Seite 87-98 |h Online-Ressource |w (DE-627)GRUY000002186 |w (DE-600)2588286-7 |w (DE-576)337259712 |x 2191-0162 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2021 |g number:2 |g day:05 |g month:04 |g pages:87-98 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1515/dmpt-2020-0173 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_GRUY | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 936 | b | k | |a 44.38 |j Pharmakologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 36 |j 2021 |e 2 |b 05 |c 04 |h 87-98 | ||